Iksuda signs licence agreement with Femtogenix for solid tumours
Iksuda Therapeutics and Femtogenix have signed a licensing agreement for antibody-drug conjugates.
Read More
Tag: Femtogenix
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
